Navigation Links
GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Cancer Vaccine
Date:12/17/2007

PHILADELPHIA, Dec. 17 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX(R). A complete response letter is issued by FDA's Center for Biologics Evaluation and Research (CBER) when the review of a file is completed and questions remain to be answered prior to approval. GSK will work closely with the FDA to prepare its response, which it intends to submit to the agency as soon as possible.

"We have already started addressing the questions and will be engaged in discussions with the FDA to finalize our responses," said Barbara Howe, M.D., Vice President and Director, North American Vaccine Development, GlaxoSmithKline. "Our discussions with the agency continue to be positive and constructive, and we are working diligently to resolve any outstanding questions to bring CERVARIX(R) to the U.S. market."

The application filed for the GSK cervical cancer vaccine included safety, efficacy and immune response data from clinical trials involving almost 30,000 females 10 to 55 years of age from ethnically and racially diverse populations.

To date, CERVARIX(R) has been approved in 45 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in more than 27 additional countries including Japan. GSK also submitted CERVARIX(R) to the World Health Organization (WHO) for prequalification in September 2007.

Notes to Editors

Burden of Cervical Cancer

Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and over 280,000 women will die from it each year.(1) In the United States, after breast cancer, cervical cancer is the second leading cause of cancer death in women ages 20 to 39.(2)

About GlaxoSmithKline

GlaxoSmithKline-one of the world's leading research-based pharmaceutical and healthcare companies-is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit http://www.gsk.com/media.

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world -- an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children from up to six diseases in one vaccine.

CERVARIX(R) is a registered trademark of the GlaxoSmithKline group of companies.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.

References:

1. World Health Organization. Initiative for Vaccine Research.

http://www.who.int/vaccine_research/diseases/hpv/en/ Accessed on May

2, 2007.

2. Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2005.

Cancer Journal for Clinicians 2005; 55; 10-30

Enquiries:

UK Media enquiries: Philip Thomson (020) 8047 5502

Alice Hunt (020) 8047 5502

Joss Mathieson (020) 8047 5502

Claire Brough (020) 8047 5502

US Media enquiries: Nancy Pekarek (215) 751 7709

Mary Anne Rhyne (919) 483 2839

Liad Diamond (919) 483 2839

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564

Sally Ferguson (020) 8047 5543

US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002

Tom Curry (215) 751 5419

Biologicals: Stella Gu +32 2 656 3533

Alice Grasset +32 2 656 8774


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... ... Mother Nature isn’t the only mom that loves the garden. Mothers everywhere love ... women with more than just a bouquet of flowers. Give mom, or any special ... Vibrant, Edible, Compact Plants from BrazelBerries: , For a gift that adds year-round color ...
(Date:5/4/2016)... ... May 04, 2016 , ... World ... the Everlasting Glove, a sports invention that aids in the improvement of the ... industry is worth $9 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:5/4/2016)... CO (PRWEB) , ... May 04, 2016 , ... ... of observational and interview techniques, seeks to add a deeper understanding of the ... strengths and weaknesses, and each answers different yet important questions. , In a ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... children has donated 100 of its innovative kicking trainers to St. Jude Children’s ... The SOCKIT is a durable, lightweight rubber band designed to teach children how ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... million in grants to identify, fund and implement ideas aimed at improving care ... Medicaid. , “Part of our vision for Trinity Health is to drive ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... According to a new market ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... (BCI) market  is expected to reach a value of ... expand at a CAGR of 14.9 % during the ... BCI device provides collaboration between the brain and an ...
(Date:5/4/2016)... , May 4, 2016  It,s time for an upgrade. There are many medical ... brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  ... as a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology: